Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5- fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2831-2840

  Louie, Arnold ^a   Liu, Weiguo ^a   Miller, Dorothy A ^a   Sucke, Alana C ^a   Liu, Qing Feng ^a   Drusano, George L ^a   Mayers, Martin ^b   Miller, Michael H ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; CANDIDA ALBICANS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; ENDOCARDITIS; ENDOPHTHALMITIS; HEART VALVE; MALE; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; RABBIT; VITREOUS BODY;

EID: 0032805644     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2831     Document Type: Article

References (50)

1. Akaike, H. 1974. A new look at the statistical model identification. IEEE Trans. Automated Control 19:716-723.
2. Alder, M. E., H. Vellend, D. M. McNeely, S. L. Walmsley, and W. L. Gold, 1995. Use of fluconazole in the treatment of candidal endophthalmitis. Clin. Infect. Dis. 28:657-664.
3. Alm, A. 1992. Ocular circulation, p. 198-227. In W. M. Hart, Jr. (ed.), Adler's physiology of the eye: clinical applications, 9th ed. Mosby Year Book, Boston, Mass.
4. Anaissie, E. J., D. M. Kontoyiannis, C. Huls, S. E. Vartivarian, C. Karl, R. A. Prince, J. Basso, and G. P. Bodey. 1995. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis. 172:599-602.
5. Andriole, V. T., H. M. Kravetz, W. C. Roberts, and J. P. Utz. 1962. Candida endocarditis. Clinical and pathologic studies. Am. J. Med. 32:251-285.
6. Ayestaran, A., R. M. Lopez, J. B. Montoro, A. Estibalez, L. Pou, A. Julia, A. Lopez, and B. Pascual. 1996. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob. Agents Chemother. 40:609-612.
7. Banerjee, P., Q.-F. Liu, A. Louie, M. Shayegani, H. Taber, G. Drusano, and M. Miller. 1997. Comparison of checkerboard isobolograms and computer generated 3D-plots for evaluation of the in-vitro interactions between antifungal drugs, abstr. C-252a, p. 164. In Abstracts of the 97th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
8. Bannatyne, R. M., and R. Cheung. 1997. Discrepant results of amphotericin B assays on fresh versus frozen serum samples. Antimicrob. Agents Chemother. 12:550.
9. Bennett, J. E. 1977. Flucytosine. Ann. Intern. Med. 86:319-321.
10. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990 Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl. 3):S318-S326.
11. Calderone, R. A., M. F. Rotondo, and M. A. Sande. 1978. Candida albicans endocarditis: ultrastructural studies of vegetation formation. Infect. Immun. 20:279-289.
12. Chavanet, P. Y., I. Garry, N. Charlier, C. Caillot, J. P. Kisterman, M. D'Athis, and H. Portier. 1992. Trial of glucose versus fat emulsion preparation of amphotericin for use in HIV infected patients with candidiasis. Br. Med. J. 305:921-925.
13. Chemlal, K., L. Saint-Julien, V. Joly, R. Farinotti, N. Seta, P. Yeni, and C. Carbon. 1996. Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob. Agents Chemother. 40:263-266.
14. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
15. Durack, D. T., P. B. Beeson, and R. G. Petersdorf. 1973. Experimental bacterial endocarditis. III. Production and progress of the disease in rabbits. Br. J. Exp. Pathol. 54:142-151.
16. Filler, S. G., M. A. Crislip, C. L. Mayer, and J. E. Edwards, Jr. 1991. Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob. Agents Chemother. 35:288-292.
17. Fisher, J. F. 1983. Penetration of amphotericin B into the human eye. J. Infect. Dis. 147:164.
18. Granich, G. G., G. S. Kobayashi, and D. J. Krogstad. 1986. Sensitive highpressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob. Agents Chemother. 29:584-588.
19. Grant, S. M., and S. P. Clissold. 1990. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916.
20. Green, W. R., J. E. Bennett, R. D. Goos. 1965. Ocular penetration of amphotericin B: a report of laboratory studies and a case report of postsurgical cephalsporium endophthalmitis. Arch. Ophthalmol. 73:769-775.
21. Hallum, J. L., and T. W. Williams, Jr. 1993. Candida endocarditis, p. 357-369. In G. P. Bodey (ed.), Candidiasis: pathogenesis, diagnosis, and treatment, 2nd ed. Raven Press, New York, N.Y.
22. Heinemann, V., D. Bosse, U. Jehn, B. Kahny, K. Wachholz, A. Debus, P. Scholz, H.-J. Kolb, and W. Wilmanns. 1997. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob. Agents Chemother. 41:1275-1280.
23. Jones, D. B., M. T. Green, M. S. Osato, P. H. Broberg, and L. O. Gentry. 1981. Endogenous Candida albicans endophthalmitis in the rabbit. Chemotherapy for systemic effect. Arch. Ophthalmol. 99:2182-2187.
24. Jorgensen, J. H., G. A. Alexander, J. R. Graybill, and D. J. Drutz. 1981. Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob. Agents Chemother. 20:59-62.
25. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested in Candida albicans. Antimicrob. Agents Chemother. 41: 1392-1395.
26. Lee, J. W., M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718.
27. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. A. Gordon. 1994. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect. Immun. 62:2761-2772.
28. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. A. Gordon. 1995. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis. J. Infect. Dis. 171:406-415.
29. Louie, A., P. Banerjee, G. L. Drusano, M. Shayegani, and M. H. Miller. 1999. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob. Agents Chemother. 43:2841-2847.
30. Louie, A., Q.-F. Liu, G. L. Drusano, W. Liu, M. Mayers, E. Anaissie, and M. H. Miller. 1998. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob. Agents Chemother. 42:1512-1514.
31. Louie, A., G. L. Drusano, P. Banerjee, Q.-F. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
32. Maddux, M. S., and S. L. Barriere. 1980. A review of the complications of amphotericin B therapy; recommendations for prevention and management. Drug Intell. Clin. Pharm. 14:177-181.
33. Madu, A., C. Cioffe, U. Mian, M. Burroughs, E. Tuomanen, M. Mayers, E. Schwartz, and M. Miller. 1994. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid. Antimicrob. Agents Chemother. 38:2111-2115.
34. Martin. E., F. Maier, and S. Bhakdi. 1994. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob. Agents Chemother. 38:1331-1338.
35. Mian, U. K., M. Mayers, Y. Garg, Q.-F. Liu, G. Newcomer, C. Madu, W. Liu, A. Louie, and M. Miller. 1998. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. J. Ocul. Pharmacol. Ther. 14:459-471.
36. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing for yeast. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
37. Odds, F. C. 1988. Candida endocarditis, myocarditis, and other cardiovascular Candida infections, p. 175-180. In F. C. Odds (ed.), Candida and candidosis. A review and bibliography, 2nd ed. Bailliere, Tindall, London, United Kingdom.
38. Park, S. S., D. J. D'Amico, B. Paton, and A. S. Baker. 1995. Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole. Antimicrob. Agents Chemother. 39:958-963.
39. Petrou, M. A., and T. R. Rogers. 1991. Interactions in vitro between polyenes and imidazoles against yeast. J. Antimicrob. Chemother. 27:491-506.
40. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients with neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331:1325-1330.
41. Rubinstein, E., E. R. Noreiga, M. S. Simberkoff, R. Holzman, and J. J. Rahal, Jr. 1975. Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine 54:331-344.
42. Sabra, R., and R. A. Branch. 1990. Amphotericin B nephrotoxicity. Drug Saf. 5:94-108.
43. Sanati, H., C. F. Ramos, A. S. Bayer, and M. A. Ghannoum. 1997. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob. Agents Chemother. 41:1345-1348.
44. Savani, D. V., J. R. Perfect, L. M. Cobo, and D. T. Durack, 1987. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob. Agents Chemother. 31:6-10.
45. Sugar, A. M., C. A. Hitchcock, P. F. Troke, and M. Picard. 1995. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39:598-601.
46. Venditti, M., F. De Bernardis, A. Micozzi, E. Pontieri, P. Chirletti, A. Cassone, and P. Martino. 1992. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin. Infect. Dis. 14:422-426.
47. Walsh, T. J., J. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab. Anim. Sci. 38:467-471.
48. Walsh, T. J., J. Lee, S. Aoki, F. Mechinaud, J. Bacher, J. Lecciones, V. Thomas, M. Rubin, and P. A. Pizzo. 1990. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev. Infect. Dis. 12(Suppl. 3):S307-S317.
49. Wise, G. J., P. J. Kozinn, and P. Goldberg. 1980. Flucytosine in the management of genitourinary candidiasis: 5 years of experience. J. Urol. 124: 70-72.
50. Witt, M. D., and A. S. Bayer. 1991. Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis. Antimicrob. Agents Chemother. 35:2481-2485.